NO Image

3rd International Conference on Cancer Molecular Targets and Therapeutics in Clinical Oncology

Nov 14-15, 2022


San Francisco, United States of America

LexisConferences holds regular yearly meetings that are design to share and connect with scientists all over the world. We most enthusiastically announce “3rd International Conference on Cancer Molecular Targets and Therapeutics in Clinical Oncology” which is to be held during November 14-15, 2022 at San Francisco, USA.

The main theme of the conference is Innovation in Molecular Targets and Projections of Novel Therapeutic Approaches.

Cancer Molecular Targets 2022 aims to provide a platform where the key strategic objective of this meeting is to communicate science and medical research between academia, and industry. Through inspiring sessions and whims of networking, you will learn to be even more audacious and bold than you are now and free to grow your mind, grow your business, and grow your bottom line. We can relieve you of the time and resource-draining elements of the events that you plan to hold. Poster and oral presentations, and thesis presentations will be included in the Conference Program.

We can relieve you of the time and resource-draining elements of the events that you plan to hold. This conference is intended to deliver a miscellaneous and current education that will keep medical professionals up to date with the latest methodologies, strategies and the present update in the field of Clinical Oncology.

The goal of organizing the Cancer Molecular Targets 2022 is to provide exposure to technologies and to deliver information about research work proceeding on Clinical Oncology.

If you would like to give a talk at the conference, please contact Program Manager.


Conference Name



 Cancer Molecular Targets 2022

San Francisco, USA

NOV 14-15, 2022






Cancer Therapeutics Market Outlook - 2026

The global cancer therapeutics market size was valued at $98,900 million in 2018 and is estimated to reach at $180,193 million by 2026, registering a CAGR of 7.7% from 2019 to 2026. Cancer therapeutics involves the use and administration of chemotherapy and oncology drugs to treat cancer.

Increase in cancer prevalence, surge in collaboration between pharmaceutical companies, and rise in cancer research are the key factors that augment the growth of the cancer therapeutics market. Furthermore, growth in geriatric population is expected to boost the market growth.

However, high cost associated with oncology drug development along with adverse effects associated with cancer therapeutics are some of the factors that restrain the market growth. Conversely, the upsurge in demand for personalized medicine and high potential of developing nations is expected to provide new opportunities for the market players in future.

Oncology Market Research Insights

The increasing adoption of radiotherapy equipment is expected to drive radiation oncology market growth through 2021. A key market trend expected to gain traction during the same forecast period is the increasing demand for proton therapy.

Overview of the global radiation oncology market

Technavio’s research analysis on the global radiation oncology market identifies that the increasing adoption of radiotherapy equipment will be one of the major factors that will have a positive impact on the growth of the market. The healthcare industry across the world highly relies on radiotherapy to manage most types of cancers. Different types of radiation therapies are used on more than half of all patients who are suffering from cancer. It has been estimated that approximately 9.5 million patients will be diagnosed with cancer by 2025. As a result, the low and mid-income countries are witnessing a rise in the installation of radiotherapy devices. It has been observed that from 1998 to 2010, the number of radiation therapy machines installed in Africa has increased by more than 75%. Radiotherapy is also recommended in high-income countries to cure localized diseases, palliate symptoms, and control the disease for incurable cancers. Our market research analysts predict that this market will grow at a CAGR of more than 5% by 2021.

The outsourcing of biosimilar manufacturing activities, a rising number of strategic collaborations, increasing cancer awareness, and a rise in R&D are the major trends impacting the global oncology biosimilars market.